[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March 16, 2011

Reexamining Metrics for Glucose Control

Author Affiliations

Author Affiliations: Department of Internal Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle.

JAMA. 2011;305(11):1132-1133. doi:10.1001/jama.2011.314

The hemoglobin A1c (HbA1c) assay was first used more than 30 years ago as a marker of diabetes control. Despite its availability for 2 decades, HbA1c testing did not assume a central role in diabetes care until the publication of 2 major clinical trials. The Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated that HbA1c level strongly predicts risk of microvascular complications associated with type 1 and type 2 diabetes, respectively.1,2 Largely consequent to these findings, HbA1c level has become the primary basis for diabetes diagnosis, treatment decisions, and assessment of quality health care. As clinical application of HbA1c measurement expands, so does the need for caution in its interpretation and appreciation of its substantial limitations.

First Page Preview View Large
First page PDF preview
First page PDF preview
×